The following is a summary of “Effects of zinc sulfate on schizophrenia symptoms in patients undergoing atypical antipsychotic pharmacotherapy,” published in the December 2022 issue of Primary care by Behrouzian, et al.

The neurological system can be negatively impacted by zinc (Zn) deficiency, which can result in cognitive difficulties. For a study, researchers sought to ascertain how Zn sulfate affected the disappearance of schizophrenia symptoms.

Double-blind intervention research was undertaken for the study in 2020. The participants’ demographic data and PANSS and HAM-D questionnaires were completed. The patients were divided into two groups of equal size (n = 44). Every eight hours, the patients received 220 mg zinc sulfate capsules; the placebo was given to the control group. Last but not least, the software was used to compare the data from the two groups.

Regarding the 88 participants’ age (P = 0.607), gender (P = 0.792), employment (P = 0.596), income (P = 0.293), sickness duration (P = 0.965), and education (P = 0.281), there were no significant differences. Before the intervention, there was no significant statistical difference between the two groups for positive symptoms (P = 0.426), negative symptoms (P = 0.891), or psychopathologic symptoms (P = 0.100). Positive symptoms did, however, significantly differ between the groups after the second week (P = 0.029), with the experimental group experiencing much fewer of them. Positive (P = 0.005), negative (P = 0.036), and psychopathological (P = 0.002) symptoms in both groups were significantly different in the fourth week after therapy (P = 0.002). Also, by the sixth week, the experimental group had significantly fewer positive (P = 0.007), negative (P = 0.002), and psychopathological (P = 0.008) symptoms than the control group.

The results of the investigation showed that zinc sulfate helped the patients’ symptoms of schizophrenia.